US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Ziccum AB carries out list change to Nasdaq First North Growth Market and releases company description

Ziccum AB (“Ziccum” or “the Company”) announces today, November 11, 2020, that it has received approval for admission to trade on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market will be December 1, 2020.Trading in the Company's share on the Spotlight Stock Market will cease and the last day for trading on the Spotlight Stock Market will be November 30, 2020. Nasdaq's decision is subject to the condition that (i) nothing occurs in connection with the list change that could lead to a different assessment of the stock exchange, (ii) the

ZICCUM to publish White Paper on world’s first industrial air-drying of vaccines using its LaminarPace technology

The White Paper will describe in detail the integration of Ziccum AB’s LaminarPace technology into a Fill and Finish (F/F) manufacturing facility of the world’s first plant for formulating and packaging thermostable air-dried vaccines at volume. The new vaccines could be produced at an estimated -65% lower OPEX and -50% lower CAPEX cost than today’s freeze drying (lyophilization) F/F plants. The vaccines produced could be stored and transported at ambient temperatures, requiring no Cold Chain.The vast majority of today’s F/F plants – the final stage in vaccine manufacture and distribution -

ZICCUM takes lead on new pilot study of vaccine plant producing cost-effective thermostable vaccines at volume with KeyPlants as engineering partner

Ziccum has produced a pilot study, including blueprints and costings, exploring the technical and financial viability of a Fill and Finish plant producing thermostable air-dried vaccines at volume. The plan, produced in collaboration with leading modular plant construction specialist KeyPlants AB, indicates significant financial benefits from formulating and packaging vaccines based on Ziccum’s LaminarPace ambient dry-formulation technology. Ziccum will now move forward and seek strategic partnerships for establishing a pilot plant for vaccine manufacturing.One of Ziccum’s key strategic

ZICCUM AB submits patent applications for improved operation of the LaminarPace system for commercial vaccine production

Ziccum's LaminarPace system for the production of temperature-stable vaccines is already protected by approved patents. However, during ongoing work to further develop and prepare LaminarPace for commercial production, a number of new, innovative solutions have been developed. By submitting two more patent applications for central design elements Ziccum intends to strengthen and extend the protection of the company's unique production method.Ziccum CEO Göran Conradson: "We are further expanding our Intellectual Property portfolio around LaminarPace, including key details that are important

ZICCUM AB interim report January 1-June 30, 2020

Summary of the interim report - second quarter 2020 During the second quarter the company carried out a private placement of a total of 2,216,815 shares to a limited number of qualified private investors. The company received SEK 38.8 million before issue costs and approximately SEK 36.4 million after issue costs (of which approximately SEK 32.3 million was added during the second quarter and the remaining approximately SEK 6.5 million was added during July 2020). During the second quarter, the company received a loan from Almi Företagspartner Skåne AB amounting to SEK 2.0 million.April-

ZICCUM AB First Quarter Report, Q1 2020

Summary of Interim First Quarter Report 2020: Further industrial and NGO collaborations.Summary of Interim First Quarter Report 2020 Ziccum announced a further, third collaboration with an industrial partner that is developing a new, more effective method of producing measles and rubella vaccines. The goal is to both significantly reduce the cost, and increase the availability, of these childhood vaccines. We have also signed a confidentiality agreement with an important non-governmental organization (NGO) for further and more detailed discussions about how technology can help the most

ZICCUM signs Letter of Intent to explore integrating Ziccum technology into innovative vaccine biomanufacturing line

(Lund, Sweden, March 26, 2020) An innovative vaccine biomanufacturer has formally declared its intention to explore incorporating Ziccum technology into its manufacture of measles and rubella vaccines, with the ultimate aim of reducing the cost of vaccines for children.The agreement is to begin exploring the incorporation of LaminarPace, Ziccum’s dry powder drug formulation tool, into the manufacture of measles and rubella vaccines. By formulating vaccines as dry powders, LaminarPace could eliminate the need for Cold Chain refrigerated infrastructure in supply chains. Dry powder vaccines

Ziccum AB (publ) Year-end report January 1 – December 31, 2019

LUND, SWEDEN – 13 February 2020. Ziccum AB (publ), summary of the year-end report - fourth quarter 2019: Ziccum is well on its way to delivering what we promised when listing our share - to start three projects during the year to develop stable, dry vaccine formulations as well as biological drugs.CEO Statement Ziccum has a unique, patented technology - LaminarPaceTM - that enables us to manufacture biological drugs in dry form. In principle, dry form is always sought after in the development of new drugs and the benefits are many. It increases the stability of the product and thus its

ZICCUM AB submits patent application for new temperature-stable, dry-powder formulation of virus belonging to same family as Measles

Lund 20 December 2019. Temperature demands on vaccines are getting tougher, as underimmunisation becomes more urgent. As part of  the WHO’s strategic mission to vaccinate more people worldwide, it now demands that vaccines must be stored at +40 degrees C for at least three days in order to earn CTC (Controlled Temperature Chain) approval (1). Ziccum is now applying for one patent that will cover a range of dry-formulated viruses and vaccines that can meet CTC demands, including new formulations of measles vaccines.Ziccum’s new, active, temperature-stable, dry-powder formulated viruses can

ZICCUM AB engages Emerging Viral Diseases unit of Aix-Marseille University to develop dry viruses and vaccines, strengthening Ziccum’s future IP portfolio

Lund, 19th December 2019. The Emerging Virus Unit (Unité des Virus Émergents) is one of the world’s leading virology laboratories. Ziccum has now engaged UVE to use Ziccum’s technology to develop and formulate vaccines and viruses as dry powders, boosting global access to them and making them significantly faster and cheaper to transport. This collaboration will significantly strengthen Ziccum’s IP portfolio.“Underimmunisation has never been more urgent” says Ziccum CEO Göran Conradson “this decision by Unité des virus émergents (UVE) to collaborate and develop the use of our technology to

There are no items matching the current filter
There are no more items matching the current filter
Back to top